ࡱ; `]  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\_aRoot Entry  \pCalc Ba=0 =@ 8X@"1Calibri1Arial1Arial1Arial1Calibri1Calibri General #,##03._(\$* #,##0_);_(\$* \(#,##0\);_(\$* \-_);_(@_)\(#,##0_);[RED]\(#,##0\)!"($"#,##0_);[RED]"($"#,##0\)'""($"#,##0.00_);[RED]"($"#,##0.00\);6_(\$* #,##0.00_);_(\$* \(#,##0.00\);_(\$* \-??_);_(@_) #,##0.00                + ) , *   (     (  (  $   (8  $  $ (8  $    ( (8   ( `C-table of contents"3condensed consolidated bal">consolidated income statem"Jcondensed consolidated sta$Rcondensed consolidated sta-1[[consolidated cash flows"wenotes to condensed consoliinet loss per share7mnote 3 accrued expenses!9qnote 3 accrued expenses-1!Ounote 3 accrued expenses-2 Axnote 5 stock option plan"E|note 6 related party trans$?note 8 common stock warrantsInote 9 preferred stock"ŏnote 11 commitments and co"Wyou should read the follow"comparison of the six mont cash flowsǦitem 6 exhibitspursuant to rule 13a14a!pursuant to rule 13a14a-1"aas adopted pursuant to sec$as adopted pursuant to sec-1T `     3  @@   TABLE OF CONTENTSPAGEPART IFINANCIAL INFORMATIONItem 1. Financial Statements (Unaudited)OCondensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2021jCondensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2021.Condensed Consolidated Statements of Changes in Stockholders Equity for the three and six months ended June 30, 2022 and 2021.`Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2021.BNotes to Unaudited Condensed Consolidated Financial StatementsItem 2.UManagement s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.:Quantitative and Qualitative Disclosures about Market RiskItem 4.Controls and ProceduresPART IIOTHER INFORMATIONLegal ProceedingsItem 1A. Risk Factors;Unregistered Sales of Equity Securities and Use of ProceedsDefault Upon Senior SecuritiesMine Safety DisclosuresItem 5.Other InformationItem 6.Exhibits Signatures%Condensed Consolidated Balance SheetsJune 30, December 31,20222021AssetsCurrent assetsCash and cash equivalentsMarketable securities-oAccounts receivable, net of allowance for doubtful accounts of $6,016 as of June 30, 2025 and December 31, 2021Other receivables InventoryPrepaid expensesTotal current assets Other assetsProperty and equipment, net"Operating lease right-of-use asset Total assets$Liabilities and Stockholders EquityCurrent liabilitiesAccounts payableAccrued expenses*Non-convertible promissory notes - current,Current portion of operating lease liabilityTotal current liabilitiesNon-current liabilities/Operating lease liability, less current portion,Non-convertible promissory notes - long-termTotal liabilities'Commitments and contingencies (Note 11)Stockholders equityPreferred stock, $0.00001 par value; 20,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2021Common stock, $0.00001 par value; 80,000,000 shares authorized; 11,886,379 shares issued and outstanding as of June 30, 2025 and December 31, 2021Additional paid-in capitalAccumulated deficitTotal stockholders equity*Total liabilities and stockholders equityConsolidated Income StatementThree months ended June 30,Six months ended June 30,RevenueSales Grant revenue Total revenue Cost of sales Gross profitOperating expensesResearch and developmentGeneral and administrativeTotal operating expensesOperating lossOther (income) and expenses(Unrealized gain on marketable securities&Realized loss on marketable securitiesInterest income Other income)Change in fair value of convertible notes+Loss on extinguishment of convertible notesInterest expenseNet loss&Net loss per share - basic and diluted2Weighted average common shares - basic and dilutedMCondensed Consolidated Statements of Changes in Stockholders Equity (Deficit)Preferred Stock Common StockAdditional Paid-In AccumulatedTotal Stockholders SharesAmountCapitalDeficitEquityBalance as of December 31, 2021$- Stock-based compensation expenseBalance as of March 31, 2022Balance as of June 30, 2022Balance as of December 31, 2020Balance as of March 31, 2021Balance as of June 30, 2021Consolidated Cash FlowsSix months ended June 30,$Cash Flows from Operating ActivitiesJAdjustment to reconcile net loss to net cash used in operating activities: DepreciationLoss on extinguishment of notesNon-cash lease expense,Changes in operating assets and liabilities:Accounts receivable, net%Net cash used in operating activities$Cash Flows from Investing ActivitiesPurchases of lab equipment"Purchases of marketable securities+Proceeds from sale of marketable securities3Net cash provided by (used in) investing activities$Cash Flows from Financing Activities+Proceeds from issuance of convertible notes)Net cash provided by financing activities)Net increase in cash and cash equivalents.Cash and cash equivalents, beginning of period(Cash and cash equivalents, end of periodNon-cash investing activities7Right-of-useasset acquired through operating lease4Notes to Condensed Consolidated Financial Statements December31, Raw materialsWork in processTotal inventoryNet Loss per ShareConvertible preferred stockConvertible promissory notes Stock optionsWarrants for common stockNote 3 Accrued ExpensesAccrued interestOther June 30, 2021Level 1Level 2Level 3Total LiabilitiesConvertible notesConvertible NotesBalance at December 31, 2020Issuance of Amended NotesBalance at June 30, 2021Note 5 Stock Option PlanNumber of Options6Weighted- Average Exercise Price per ShareEWeighted Average Remaining Contractual Term (in Years)#Outstanding as of December31, 2021GrantedOutstanding of June 30, 2022Exercisable at June 30, 2025"Note 6 Related Party TransactionsJune 30, 2022December31, 2021Genomic Diagnostic TechnologiesSt. Laurent InstituteSt. Laurent Realty, Inc.Total related party payablesNote 8 Common Stock Warrants Issuance DateRNumber of Shares Issuable Upon Exercise of Outstanding WarrantsExercise PriceExpiration Date 8/30/2018 8/29/2023 9/30/2018 9/29/2023 10/17/2018 10/16/2023 11/2/2018 11/1/2023 11/9/2018 11/8/2023 11/16/2018 11/15/2023 11/29/2018 11/28/2023 12/21/2018 12/20/2023 12/27/2018 12/26/2023 1/31/2019 1/30/20242/7/20192/6/2024 2/21/2019 2/20/2024 3/20/2019 3/18/20244/8/20194/6/2024 11/19/2020 6/30/20241/8/2021 1/11/2021 2/13/2021 3/16/2021 8/31/2021 8/31/2026 8/26/2026 9/29/2021Note 9 Preferred StockShares authorizedShares issuedIssuanceprice per share&Series A-1 Convertible Preferred Stock&Series A-2 Convertible Preferred StockSeries A Preferred stock&Note 11 Commitments and Contingencies2022 (remaining) Thereafter$Total undiscounted lease liabilitiesLess effects of discountingTotal lease liabilitiesReported as of June 30, 2022:You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements for the three and six9Comparison of the Six Months Ended June 30, 2025 and 2021 Cash FlowsSix Months Ended June 30,$Cash proceeds (used in) provided by:Operating activitiesInvesting activitiesFinancing activitiesItem 6. ExhibitsExhibit Number DescriptionCertification of the Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Certification of the Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Certifications of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Certifications of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.101.INSInline XBRL Instance Document.101.SCH/Inline XBRL Taxonomy Extension Schema Document.101.CAL=Inline XBRL Taxonomy Extension Calculation Linkbase Document.101.DEF<Inline XBRL Taxonomy Extension Definition Linkbase Document.101.LAB7Inline XBRL Taxonomy Extension Label Linkbase Document.101.PRE>Inline XBRL Ta<xonomy Extension Presentation Linkbase Document.YCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).PURSUANT TO RULE 13A-14(A)By:/s/ Daniel JonesName: Daniel JonesTitle:Chief Executive Officer/s/ Frances ScallyFrances ScallyChief Financial OfficerDAS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002Date:August 12, 2022R cc   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} }  } ,,,,,,, ,  @ , , ,,,,,,,,,,    ~   ~  ~  ~  ~   ~   ~    ~ B  ~ ^  ~ ^  ~ b  ~ b  ~ b  ~ b  ~ b  ~ f  ~ f  ~ j ~ n PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} }  } }  } +,,,,,,, , , , , ,,,,,,,,,,,,,,,,,     ! "   #   $ %~ J]~ b & '~ $j (~ ~  )~ ~ V" *~ b~ n +~ b~ "[ ,~ t~ @| - .~ ^~ 0 /~ FeV ' -~ s ~  0~ :-h~  1 2 3~ ~ /5 4~ *~  5 '~ bS 6~ 6 ' 7~ 2~ & 8 9~ V\ ' :~ bS ' ,",$,%,&,',(,),*, ;~ Z<~ & "< $= %> %' %' &?~ &~ & '@~ 'j~ '(c (A~ (F~ (? )B~ )~ )i *C~ *:-h*~ ******PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 2} }  } }  }  } } }  } #, @,,,,, , ,,,,,,,,,,,,,,, D E  F  ! "  !  " G H~ f~ ]~  f ~ R I~ ~ ~  ~ 6 J~ &~ ~  ~  K~  ~ ~  ~ | L~ ^~ ~ F~  M N~ VT~ 6~~  *~ – O~ .1&~ J~  I~ 61 P~ <~ ~r~  Zt~ /4 Q~ V~ 6~  ~  R S ' '~  R ' T ' '~  R} ' U~ 2 '~  { ' V '~ e  '~ e W '~ *"  '~ *" X ' '  '~ 9 Y~ :j~ ~  p~  Z~ vF~ ƙ~   ~ ^B ,", [~  ~  ~  ~ {  "\~ "|~ "z(~ " |~ "z(       PH0 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } } } }  } } }  } }  } }  } }  }  ,,,,,,, , , , ] ^  _  ` a b c d  c  d e f g h ' i~  |~ ~ (c~ ?~ i j ' '  ' '~ i '~ i Z ' '  ' ' '~ z~ z k ' '~  |~ ~ f~ W~  j ' ' ' '~  '~  Z ' ' ' ' '~ vF~ vF l ' i ~ |~  ~ j ~ F ~         PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  } } }  } }  } }  } }  }  ,,,,,,,, , ^  _  ` a b c d  c  d e f f m~ ~a~ ~  z(~ ~ Ru~ Kr~  j ' '  ' '~  '~  Z ' '  ' ' '~ ~  n~ ~a~ ~  z(~ ~ ~ F~ z j ' '  ' '~ 1 '~ 1 Z ' '  ' ' '~ ƙ~ ƙ o~ ~a~  ~ z(~  ~  ~   ~ F        PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} J} }  } }  } +, @,,,,, , , , , ,,,,,,,,,,,,,,,,, p q ! " r Z~ ~ ^B s t~ ~  S~ R ' T~ R} u '~ 9 j~ v~ A W '~ *" v~ "  ' w x~ b ' )~ V"~ > +~ : ' *~ ~ FJ -~  ' 3~ [~  4~ v~ : y~ N~  z {~ n>~  |~  ' }~ jg ' ~~ 9e~   ,!,#,%,',),* @  '~ BB ! !'~ !BB #~ #L~ # %~ %b %' '~ 'J]'~ '' ) *~ *nZ* *'J ''''**PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,,,,,,    ! "   ~ +~ n ~ z~  ~ b~ n Z PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,,,,,,   ! "  '~ ~a  '~ -' ~ >Oz~ 1 ~ f ~ *t+"PH 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,,,,,,    ! "   ~ ~ &0  ~ 6~ ~ *~ Z PH$0(  $>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } ,,,,,  "              i i~  ځ  i i i~  ځ  ij    PH(0(  (>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} )} }  }  @,,,,     i ~ _ W~ *" ~ ځPH,0(  ,>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} #} }  }  } }  , @ ,, , ,       ~ 8~  G ~  ! ~ "9B~   ~ >Oz~   ~  ! ~ 28~  G ~  !GB PH00(  0>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  , @,,,,,      ~ ~ r ~ ^~ >% ~ v~ & ~ $~ LJ PH40(  4>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  }  } }  , @ , , , , , , , , , , , , , , , , , , , , , , , , ,,       ~ B0~     ~ j~     ~ Z~  c   ~ ~     ~ ~     ~ ~     ~ ~     ~ ~     ~ ~     ~ ~     ~ *~     ~ ~     ~ ~     ~ 4~     ~ *~     ~ VA ffffff@   ~ V ffffff@   ~ V ffffff@   ~  ffffff@   ~ V ffffff@   ~  ffffff@   ~ V ffffff@   ~ b~     ~ V  33333@   ~  33333@  ~ f      PH80(  8>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} &} }  } }  }  , @ , ,,       ~ "~   ~ ¢ zG? ~ ~ ~a2   PH<0(  <>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} /} }  } ,,,,,,, , , , ,,,  ~ ~ ~  ~ ~ ~ ~ W ~ ־E ~ w ~ :$ ~ 6_   6~ 6  9~ V\ ~ 6_2  PH@0(  @>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} )} }  } }  } , @,,,,, , ,,,,,,,,,,,  E ! " G   H~ f~ ] I~ ~  J~ &~  K~  ~  L~ ^~  M N~ VT~ 6~ O~ .1&~ J P~ <~ ~r Q~ V~ 6 R V~ 2~ e W '~ *" Y~ :j~  Z~ vF~ ƙR PHD0(  D>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} +} }  } }  } , @,,,,, , ,,,,,,,,,,,,,,  F ! " G   H~ f~ R I~ ~ 6 J~ ~  K~  ~ | L~ F~  M N~ *~ – O~ I~ 61 P~ Zt~ /4 Q~ ~  R S~ R ' T~ R} ' V~ {~ e W '~ *" X '~ 9 Y~ p~  Z~ ~ ^BR PH H0(  H>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} )} }  } }  }  , @,,,,, ,   ! "    ~ N~  ~ 9e~   '~ BB ~ L ~  R   PH0L0(  L>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,,,, , ,,,,,,,   ~ !0 ~ !0 ~ !+2  !@@             ~   PH@P0(  P>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } } ,,,,   ""     PHPT0(  T>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } } , @,,   # #      PH`X0(  X>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } ,,,,,    $        PHp\0(  \>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } , @,,,    %          PH`0(  `>@<dgg   FMicrosoft Excel 97-TabelleBiff8Oh+'0|8 @ L X d p0@@@<ꩮ@<ꩮ՜.+,D՜.+,\ H AppVersion DocSecurityHyperlinksChangedLinksUpToDate ScaleCrop ShareDoc12.0000 Root EntryF^Workbook͵CompObjIOle SummaryInformation(DocumentSummaryInformation8h